NICE Backs Weight-Loss Jab to Help Prevent Heart Attacks and Strokes
The UK’s medicines watchdog, National Institute for Health and Care Excellence (NICE), has approved the use of a weight-loss injection to help prevent life-threatening cardiovascular events, including heart attack and stroke.
The decision marks a significant shift in how weight-loss medications are used within the NHS, with the drug semaglutide—commonly known by the brand Wegovy—now recommended not just for weight management, but also for protecting heart health.
What NICE has approved
Under the new guidance, the weekly injection will be offered to adults who:
- Have previously experienced a heart attack, stroke, or circulation problems
- Have a body mass index (BMI) of 27 or above
The treatment will be used alongside other medicines, such as statins, and combined with healthy lifestyle changes like improving diet and increasing physical activity.
Around 1.2 million people in England are expected to be eligible for the jab as it is gradually introduced across the NHS.
Evidence behind the decision
The recommendation is based on strong clinical trial results. In a large international study involving more than 17,000 people, those who received semaglutide were about 20% less likely to have serious heart-related events, such as heart attacks or strokes, compared to those who did not receive the drug.
Researchers also found that the benefits appeared even before significant weight loss, suggesting the medication may have a direct positive effect on heart health—not just through helping people lose weight.
A new approach to prevention
Health experts say the move could be a “game changer” in preventing repeat cardiovascular events. People who have already had a heart attack or stroke are known to be at much higher risk of experiencing another.
By adding semaglutide to existing treatments, clinicians hope to:
- Reduce repeat hospital admissions
- Lower the number of preventable deaths
- Improve long-term quality of life for patients
What this means for health and social care
For professionals working in health and social care, the announcement highlights a growing focus on preventative treatment rather than just managing illness.
Key implications include:
- Supporting patients to access and understand new treatments
- Encouraging lifestyle changes alongside medication
- Monitoring patients for effectiveness and side effects
Key message
While often seen as a “weight-loss jab,” NICE’s backing of semaglutide signals a broader role in healthcare. The drug is now being positioned as a preventative treatment for serious heart conditions, offering new hope for those at high risk of future heart attacks and strokes.